⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 9, 2024Neurology

Treatment with Eptinezumab Reduces Brain Fog and Increases the Number of Good Days Per Month in Patients with Chronic Migraine in a Real-world Setting (P8-12.009)

Dawn C. Buse Seema Soni-Brahmbhatt Divya Asher Richard B. Lipton

View Full Paper

Ask AI

Bookmark

Share

Abstract

To evaluate the real-world effectiveness of eptinezumab on "brain fog" and the number of "good" days/month in adults with chronic migraine (CM).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Buse et al. (2024) studied this question.

synapsesocial.com/papers/68e6fcc5b6db64358767736e https://doi.org/10.1212/wnl.0000000000204566

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Real-world effectiveness of eptinezumab in chronic migraine—increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fog2025 · 1 citations
2Real-world effectiveness of eptinezumab in chronic migraine—increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fog2025
3Real-world Effectiveness of Eptinezumab in Chronic Migraine: A 4-year Retrospective Longitudinal Cohort Study (P10-15.003)Cohort Study · 2026
4Impact of Psychiatric Conditions on the Real-world Effectiveness of Eptinezumab Treatment in Patients with Chronic Migraine (P4-12.005)2024
5Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE—The First Italian Multicenter, Prospective, Real-Life Study2024 · 11 citations